- Home
- FENG vs CMMB Comparison
FENG vs CMMB Comparison
Compare FENG & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FENG | CMMB |
|---|---|---|
| Founded | 1998 | 2004 |
| Country | China | Israel |
| Employees | N/A | 12 |
| Industry | Broadcasting | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.1M | 20.5M |
| IPO Year | 2011 | 2023 |
Fundamental Metrics
Financial Performance| Metric | FENG | CMMB |
|---|---|---|
| Price | $1.46 | $2.48 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $25.00 |
| AVG Volume (30 Days) | 1.8K | ★ 122.5K |
| Earning Date | 05-12-2026 | 05-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 101.67 |
| EPS | N/A | ★ 0.04 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $65.25 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.39 | $1.35 |
| 52 Week High | $3.65 | $3.55 |
Technical Indicators
Market Signals| Indicator | FENG | CMMB |
|---|---|---|
| Relative Strength Index (RSI) | 46.98 | 52.46 |
| Support Level | $1.44 | $1.47 |
| Resistance Level | $1.52 | $2.92 |
| Average True Range (ATR) | 0.02 | 0.21 |
| MACD | -0.00 | -0.04 |
| Stochastic Oscillator | 55.62 | 21.86 |
Price Performance
Historical ComparisonAbout FENG Phoenix New Media Limited
Phoenix New Media Ltd is a media company providing premium content on an integrated platform across the internet, mobile and TV channels in China. The company organizes its operations into two main segments: Net advertising services and Paid services. It provides its content and services through three channels: ifeng.com channel, video channel, and mobile channel. The company also offers a wide range of paid services including mobile value-added services, games, and content sales. It generates the majority of its revenue from Net advertising services. Geographically, it derives all of its revenue from PRC.
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.